Dysregulation of CDKs is often associated with cancer. Overexpression or mutation of CDKs and cyclins can lead to uncontrolled cell proliferation. For instance, CDK4/6 overactivity is commonly observed in breast cancer, making CDK inhibitors a promising therapeutic approach. Drugs like Palbociclib inhibit CDK4/6, thereby arresting the cell cycle in the G1 phase and preventing cancer cell division.
